Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia

International Journal of Infectious Diseases

Volumn 43, Issue , 2016, Pages 77-84

  Leneva, I A ^a   Burtseva, E I ^b   Yatsyshina, S B ^c   Fedyakina, I T ^b   Kirillova, E S ^b   Selkova, E P ^d   Osipova, E ^a   Maleev, V V ^c  

^a MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^c CENTRAL RESEARCH INSTITUTE OF EPIDEMIOLOGY   (Russian Federation)

^d GN Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology   (Russian Federation)

Author keywords

Influenza; Observational study; Oseltamivir; Susceptibility to antivirals; Umifenovir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ARBIDOL; OSELTAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; INDOLE DERIVATIVE; SIALIDASE;

2009 H1N1 INFLUENZA; ADULT; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE DURATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; IC50; IN VITRO STUDY; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA B VIRUS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RUSSIAN FEDERATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS ISOLATION; VIRUS PNEUMONIA; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL LINE; DOG; DRUG EFFECTS; INFLUENZA, HUMAN; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEURAMINIDASE; OSELTAMIVIR; RETROSPECTIVE STUDIES; RUSSIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84956678939     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.01.001     Document Type: Article

References (38)

1. Swine-origin influenza A (H1N1) virus-United States and other countries. MMWR Morb Mortal Wkly Rep 2009, 58:421. US Centers for Disease Control and Prevention.
2. Russian Statistical Yearbook. The incidence of selected infectious diseases. Statistics digest/Rosstat. - M., 2011. - 795 pp. Available at: http://www.gks.ru/bgd/regl/b11_13/IssWWW.exe/Stg/d2/08-18.htm.
3. Monto A., Webster R. Influenza pandemics: history and lessons learned. Textbook of influenza 2013, 20-33. John Wiley and Sons, Chichester. 2nd ed. R.G. Webster, A.S. Monto, T.J. Braciale, R.A. Lamb (Eds.).
4. Webster R.G., Govorkova E.A. Continuing challenges in influenza. Ann N Y Acad Sci 2014, 1323:115-139. 10.1111/nyas.12462.
5. Griffin M. Influenza vaccination: a 21st century dilemma. S D Med 2013, (Spec no.):110-118.
6. World Health Organization. Guidelines on the use of vaccines and antivirals during influenza pandemics: Annex 5-Considerations for the use of antivirals during an influenza pandemic. Geneva: WHO; 2004. Available at: .(accessed September 25, 2013). http://whqlibdoc.who.int/hq/2004/WHO_CDS_CSR_RMD_2004.8_eng.pdf.
7. Centers for Disease Control and Prevention. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60. Available at: (accessed March 5, 2014). http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
8. Glushkov R. Arbidol. Drugs Future 1992, 17:1079-1081.
9. Guskova T, Glushkov R. Efficacy and safety of arbidol in treating and prophylaxis of influenza: clinical trials. In: Glushkov R, editor. Arbidol-a new antiviral, immunomodulator, interferon inducer (Russian). Moscow: Timotek; 1999, p. 63-76.
10. Boriskin Y., Leneva I., Pecheur E., Polyak S. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008, 15:997-1005. 10.2174/092986708784049658.
11. Delogu I., Pastorino B., Baronti C., Nougairède A., Bonnet E., de Lamballerie X. In vitro antiviral activity of arbidol against chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 2011, 90:99-107. 10.1016/j.antiviral.2011.03.182.
12. Blaising J., Polyak S.J., Pécheur E.I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014, 107:84-94. 10.1016/j.antiviral.2014.04.006.
13. Leneva I.A., Russell R.J., Boriskin Y.S., Hay A.J. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res 2009, 81:132-140. 10.1016/j.antiviral.2008.10.009.
14. Leneva I.A., Fediakina I.T., Gus'kova T.A., Glushkov R.G. Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A (Russian). Ter Arkh 2005, 77:84-88.
15. Leneva I., Fedyakina I., Eropkim M., Gudova N., Romanovskaya A., Danilenko D., et al. Study of antiviral activity of Russian domestic anti-influenza agents in cell culture and in animal model. Vopr Virus (Russian) 2010, 3:19-27.
16. Brooks M.J., Burtseva E.I., Ellery P.J., Marsh G.A., Lew A.M., Slepushkin A.N., et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 2012, 84:170-181. 10.1002/jmv.22234.
17. Burtseva E., L'vov D., Shchelkanov M., Kolobukhina L., Prilipov A., Al'khovskiĭ S., et al. The specific features of the cocirculation of influenza viruses in the 2010-2011 postpandemic period according to the results of activities of the D. I. Ivanovsky Research Institute of Virology, Ministry of Health and Social Development of Russia (Russian). Vopr Virus 2012, 57:20-28.
18. Sominina A., Burtseva E., Eropkin M., Karpova L., Zarubaev V., Smorodintseva E. Influenza surveillance in Russia based on epidemiological and laboratory data for the period from 2005 to 2012. Am J Infect Dis 2013, 9:77-93. 10.3844/ajidsp.2013.77.93.
19. World Health Organization. Fluorometric neuraminidase inhibitor assay: standard operating procedure WHO-025. Australia: WHO Collaborating Centre for Reference and Research on Influenza; 2009. Available at: (accessed September 25, 2013). http://www.nisn.org/documents/A.%20Hurt_Protocol_for_NA_fluorescence.pdf.
20. Grambas S., Hay A.J. Maturation of influenza A virus hemagglutinin-estimates of the pH encountered during transport and its regulation by the M2 protein. Virology 1992, 190:11-17.
21. Belshe R.B., Smith M.H., Hall C.B., Betts R., Hay A.J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988, 62:1508-1512.
22. Iatsyshina S.B., Minenko A.N., Kushakova T.E., Praded M.N., Kudriavtseva A.V., Shipulin G.A., et al. Pandemic influenza A/H1N1(sw2009) in Russia: epidemiology, diagnosis, clinical picture and treatment (Russian). Ter Arkh 2010, 82:10-14.
23. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025. 10.1038/nature08260.
24. Maines T.R., Jayaraman A., Belser J.A., Wadford D.A., Pappas C., Zeng H., et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009, 325:484-487. 10.1126/science.1177238.
25. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009, 58:433-435. US Centers for Disease Control and Prevention (CDC).
26. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006, 50:2395-2402. 10.1128/AAC.01339-05.
27. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir-2008-2009 influenza season. 18 March 2009; Geneva: WHO. Available at: (accessed November 3, 2009). http://www.who.int/influenza/resources/documents/H1N1webupdate20090318_ed_ns.pdf.
28. Summary of influenza antiviral susceptibility surveillance findings, September 2010-March 2011. 6 June 2011; Geneva: WHO. Available at: (accessed July 6, 2011). http://www.who.int/influenza/gisrs_laboratory/updates/antiviral_susceptibility/en/.
29. Romanovskaia A.A., Durymanov A.M., Sharshov K.A., Zaĭkovskaia A.V., Susloparov I.M., Shestopalov A.M., et al. Investigation of susceptibility of influenza viruses A (H1N1), the cause of infection in humans in April-May 2009, to antivirals in MDCK cell culture. Antibiot Khimioter 2009, 54:41-47.
30. Fediakina I.T., Shchelkanov M.I., Deriabin P.G., Leneva I.A., Gudova N.V., Kondrat'eva T.V., et al. Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture. Antibiot Khimioter 2011, 56:3-9.
31. Govorkova E.A., Marathe B.M., Prevost A., Rehg J.E., Webster R.G. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res 2011, 91:81-88. 10.1016/j.antiviral.2011.05.008.
32. Aoki F.Y., Macleod M.D., Paggiaro P., Carewicz O., El Sawy A., Wat C., et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003, 51:123-129. 10.1093/jac/dkg007.
33. ClinicalTrials.gov. NCT01651663. A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold (ARBITR). Principal Investigator: Oleg Kiselev, Dr. Biol. Sci. Research Institute of Influenza. Available at: (accessed January 23, 2015). http://clinicaltrials.gov/ct2/show/NCT01651663?term=arbidol%26rank=1.
34. Ebell M.H., Call M., Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract 2013, 30:125-133.
35. Jefferson T., Jones M., Doshi P., Spencer E.A., Onakpoya I., Heneghan C.J. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014, 348:g2545. 10.1136/bmj.g2545.
36. Michiels B., Van Puyenbroeck K., Verhoeven V., Vermeire E., Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One 2013, 8:e60348.
37. Butler D. Tamiflu report comes under fire. Nature 2014, 508:439-440. 10.1038/508439a.
38. Santesso N., Hsu J., Mustafa R., Brozek J., Chen Y.L., Hopkins J.P., et al. Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. Influenza Other Respir Viruses 2013, 7(Suppl 2):76-81.